ObjectiveTo explore the effect and mechanism of Guanxinshu prescription (GXSP) on reducing inflammatory response in atherosclerosis (AS) in apolipoprotein E knockout (ApoE-/-) mice. MethodsForty SPF-grade male ApoE-/- mice were fed a high-fat diet for 12 weeks for the modeling of AS, and then they were randomized into the model, low-, medium-, and high-dose (1.5, 3, and 6 g·kg-1, respectively) GXSP, and atorvastatin (5×10-3 g·kg-1) groups, with 8 mice in each group. Additional eight C57BL/6J mice served as the normal group. After 4 weeks of intervention, the serum levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. Superoxide dismutase (SOD) activity and malondialdehyde (MDA) content in the aortic tissue were determined. Serum levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-18 (IL-18) were determined by enzyme-linked immunosorbent assay (ELISA). Aortic plaque area and morphology were observed via oil red O and hematoxylin-eosin (HE) staining. The protein levels of tyrosine kinase receptor (AXL), Mer receptor tyrosine kinase (MERTK), tyrosine-protein kinase receptor TYRO3, milk fat globule-epidermal growth factor 8 (MFGE8), c-Jun N-terminal kinase (JNK), nuclear factor-κB p65 (NF-κB p65), p38 mitogen-activated protein kinase (MAPK), and extracellular signal-regulated kinase 1/2 (ERK1/2) in the aortic tissue was analyzed by Western blot. Immunohistochemistry was performed to detect α-smooth muscle actin (α-SMA) and fibronectin expression in the aortic sinus. Immunofluorescence assay was used to examine the expression of cluster of differentiation 68 (CD68) and brain-specific angiogenesis inhibitor 1 (BAI1) in aortic plaques. ResultsCompared with the normal group, the model group had dyslipidemia, increased aortic plaque area (P<0.01), elevated serum levels of TNF-α, IL-1β, and IL-18 (P<0.01), decreased MDA content and SOD activity in the aorta (P<0.05,P<0.01), upregulated expression of α-SMA, fibronectin, JNK, NF-κB p65, p38 MAPK, and ERK1/2 (P<0.05, P<0.01), downregulated expressions of AXL, MERTK, TYRO3, and MFGE8 (P<0.01), increased CD68 fluorescence intensity and decreased BAI1 fluorescence intensity (P<0.01). Compared with the model group, GXSP groups and the statin group exhibited alleviated dyslipidemia, reduced aortic plaque area (P<0.05, P<0.01). The high-dose GXSP group showed declined serum levels of TC, TG, LDL-C, IL-1β, TNF-α, IL-18, and MDA (P<0.01), increased HDL-C level and SOD activity (P<0.01), upregulated expression of α-SMA, fibronectin, TYRO3, and MFGE8 (P<0.05, P<0.01), downregulated expression of JNK, NF-κB p65, p38 MAPK, and ERK1/2 (P<0.01), weakened fluorescence intensity of CD68 and enhanced fluorescence intensity of BAI1 (P<0.01). The statin group showed declined serum levels of TC, TG, LDL-C, IL-1β, TNF-α, IL-18, and MDA (P<0.05, P<0.01), increased HDL-C level and SOD activity (P<0.05, P<0.01), upregulated expression of α-SMA, fibronectin, AXL, MERTK, TYRO3, and MFGE8 (P<0.05, P<0.01), downregulated expression of JNK, NF-κB p65, p38 MAPK, and ERK1/2 (P<0.01), decreased fluorescence intensity of CD68 and increased fluorescence intensity of BAI1 (P<0.01). The medium-dose GXSP group exhibited declined serum levels of IL-1β, TNF-α, TC, LDL-C, and MDA (P<0.01), increased activity of SOD (P<0.05), upregulated expression of α-SMA, AXL, MERTK, TYRO3, and MFGE8 (P<0.05, P<0.01), downregulated expression of JNK, NF-κB p65, p38 MAPK, and ERK1/2 (P<0.01), reduced fluorescence intensity of CD68 and enhanced fluorescence intensity of BAI1 (P<0.01). The low-dose GXSP group demonstrated lowered serum levels of IL-1β, TNF-α, and TC (P<0.01), upregulated expression of AXL, MERTK, TYRO3, and MFGE8 (P<0.05, P<0.01), downregulated expression of JNK, NF-κB p65, p38 MAPK, and ERK1/2 (P<0.01), weakened fluorescence intensity of CD68 and enhanced fluorescence intensity of BAI1 (P<0.01). ConclusionGXSP can mitigate AS plaque formation, lipid metabolism disorders, and inflammatory response in ApoE-/- mice by enhancing macrophage efferocytosis and inhibiting the IL-18/MAPK signaling pathway.